JACC This Week Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry | JACC
Apr 14, 2025
Dr. Valentin Fuster dives into the groundbreaking research on early ezetimibe and statin therapy after myocardial infarction. The findings reveal that initiating ezetimibe early significantly lowers the risk of major cardiovascular events. Fuster discusses the compelling data from the SWEDEHEART registry and argues for its adoption in standard care. He addresses the benefits of combination therapy and contrasts it with late initiation. The podcast also examines the nuances of LDL levels and suggests further studies on adherence and side effects.
AI Snips
Chapters
Transcript
Episode notes
MI Often Marks First Lipid Therapy
- Many MI patients start lipid-lowering therapy only after the event, usually with high-intensity statins alone.
- Registry data show earlier dual therapy may change long-term outcomes beyond statins alone.
Early Ezetimibe Lowers Long-Term Events
- Early ezetimibe added to statin within 12 weeks reduced MACE rates compared with late or no ezetimibe.
- The early group had substantially lower event rates over a median 3.96 years follow-up.
Delay Raises Cardiovascular Death Risk
- Delaying ezetimibe was associated with higher cardiovascular death risk compared with early combination therapy.
- Hazard ratios at three years were notably higher for late or no ezetimibe versus early use.